MIRA Pharmaceuticals (MIRA) vs Scilex (SCLX)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 10, 2026.
Summary
MIRA Pharmaceuticals (MIRA) has outperformed Scilex (SCLX) over the past year, losing 44.4% versus a loss of 73.5%. MIRA Pharmaceuticals is the larger company by market cap ($31.3 million vs $20.5 million), about 1.5 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | MIRA | SCLX |
|---|---|---|
| Share price | $0.7455 | $2.92 |
| Market cap | $31.33M | $20.54M |
| 1-day change | +6.05% | -1.35% |
| YTD return | -50.63% | -61.56% |
| 1-year return | -44.37% | -73.48% |
| 5-year return | — | -98.66% |
| Forward P/E | — | 4.00 |
| EPS (TTM) | $-1.14 | $-49.70 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $2.45 | $16.81 |
| 52-week low | $0.60 | $2.62 |
| Distance from 52-week high | -69.57% | -82.63% |
| Analyst consensus | none | — |
| Avg. price target upside | +369.48% | — |
| Average volume | 585.75K | 54.13K |
| Shares outstanding | 42.02M | 7.03M |
| Employees | — | 34 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Biological Products (No Diagnostic Substances) |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- MIRA has outperformed SCLX by 29.1 percentage points over the past year.
About MIRA Pharmaceuticals
MIRA stock →MIRA Pharmaceuticals, Inc. operates as a pre-clinical-stage pharmaceutical development company with two neuroscience programs targeting a range of neurologic and neuropsychiatric disorders.
Health Care · Biotechnology: Pharmaceutical Preparations
About Scilex
SCLX stock →Scilex Holding Company focuses on acquiring, developing, and commercializing non-opioid pain management products for the treatment of acute and chronic pain. Its commercial products include ZTlido (lidocaine topical system) 1.8% (ZTlido), a prescription lidocaine topical product for the relief of neuropathic pain associated with postherpetic neuralgia (PHN), which is a form of post-shingles nerve pain; ELYXYB, a ready-to-use oral solution for the acute treatment of migraine with or without aura in adults; and GLOPERBA, a liquid oral version of the anti-gout medicine colchicine indicated for the prophylaxis of painful gout flares in adults.
Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 34 employees
MIRA vs SCLX FAQ
Which is bigger, MIRA Pharmaceuticals or Scilex?
MIRA Pharmaceuticals (MIRA) is larger, with a market capitalization of $31.33M compared with $20.54M for Scilex (SCLX).
Which stock has performed better over the past year, MIRA or SCLX?
MIRA returned -44.37% over the past 12 months, compared with -73.48% for SCLX (price return, excluding dividends). Past performance does not predict future results.
Are MIRA Pharmaceuticals and Scilex in the same industry?
Both are in the Health Care sector, but in different industries: Biotechnology: Pharmaceutical Preparations for MIRA Pharmaceuticals and Biotechnology: Biological Products (No Diagnostic Substances) for Scilex.